Figure 2.

Distant recurrence-free survival of postmenopausal, oestrogen-receptor-positive breast cancer patients in relation to the SULT1A1 genotype and adjuvant tamoxifen therapy. Solid line, patients receiving tamoxifen (Tam+); dashed line, patients who did not receive tamoxifen (Tam-). (a) Patients homozygous for the SULT1A1*1 allele. The number of events for Tam+ and Tam- were 9 and 16, respectively. (b) Patients homozygous or heterozygous for the SULT1A1*2 allele (low-activity allele). The number of events for Tam+ and Tam- were 24 and 26, respectively.